Change in HbA1c as a guide for T2D treatment intensification is steadily yielding to presence of/risk for comorbidities as pluripotent agents win guideline favor, observes a VA clinical investigator.
Elements of proper blood pressure measurement technique may seem picayune, but skipping them may cost you - here's how much.
The FDA today denied Juul Labs' premarket tobacco product applications and ordered all products removed from shelves nationwide, ending a 2-year review.
A literature review comprising ~1.3 million patients infected with SARS-CoV-2 reveals women are 22% more likely vs men to develop long COVID, yet treatment is no different.
The sodium-glucose cotransporter 1/2 inhibitor at 150 mg was associated with a significant 32% reduction in liver enzyme levels in a phase 2a clinical trial.
The 21-valent pneumococcal conjugate vaccine targets 85% of invasive pneumococcal disease in adults aged ≥65 years; 8 serotypes are exclusive to this vaccine, says Merck.
The cost of continuous glucose monitors must be covered for persons with type 1 and type 2 diabetes in the state of Illinois based on a bill signed into law this month.
As the COVID-19 pandemic swelled, quickly depleting US health care system resources, outcomes in some states were, and remain, far worse than in others.
While long COVID may be less likely following Omicron, researchers note, the sheer number of those infections in the UK should be a stark warning.
New findings suggest that HIIT may be an effective aerobic exercise option for asthma patients.
Empagliflozin was associated with a nearly 40% reduced risk of incident renal stone disease vs placebo in a large analysis of data pooled from randomized clinical trials.
DiabetesWise Pro founder highlights the 3 most beneficial website features to help clinicians compare all the available CGMs, delivery systems, AIDs, and smart pens.
Insurance companies believe the required presurgical programs reduce complications and improve outcomes but a new study strongly suggests the opposite.
Primary care clinicians are critical to screening and caring for CKD. This "In brief" slide show reviews the 2 key lab tests used to diagnose the disease.
ENDO 2022: Findings from the long-term, real-world study of meds for maintenance of meaningful weight loss support wider uptake of the agents, authors say.
Baby Boomers had more chronic health conditions and more conditions at younger ages than older adults born at the end of the Great Depression.
ENDO 2022: The large US analysis found persons with prediabetes had increased odds for heart attack of 25%, for PCI of 45%, and had nearly double the risk of having CABG.
ADA 2022: Use of flash continuous glucose monitoring in T2D patients not on insulin also reduced HbA1c and glycemic variability, a new study finds.
ADA 2022. Tirzepatide was associated with significantly greater TIR, many fewer episodes of hypoglycemia, and less glycemic excursion vs insulin degludec in SURPASS-3 CGM.
ADA 2022: Primary care patients with T2D and HbA1c >7.5% achieved as much as a 1.5% drop in HbA1c after initiating real time continuous glucose monitoring.
ADA 2022: Reduction in risk of progression to type 2 diabetes of 60% was seen in STEP program clinical trial participants with overweight or obesity.
ADA 2022: Oral semaglutide may be particularly effective for T2D patients with HbA1c ≥9% and prescribed more frequently for these patients by primary care clinicians.
ADA 2022: The protective effect of finerenone on cardiovascular and renal outcomes was not affected by initial HbA1c levels or T2D duration in analysis of data from the FIDELITY pooled cohort.
ADA 2022: Professor Hiddo Heerspink led the prespecified SURPASS-4 analysis that found tirzepatide associated with a 41% reduction in risk of a composite renal outcome.
ADA 2022: In a real-world study of nearly half a million adults with T2D followed for 5 years, the SGLT-2 inhibitor surpassed both other classes used in routine clinical care.
ADA 2022: Tirzepatide led overall to weight loss of up to 22.5% of baseline body weight with persons taking the 15 mg dose losing an average of 52 pounds.
ADA 2022: Tirzepatide, a GIP/GLP-1 receptor agonist, reduced a composite of kidney events in patients with type 2 diabetes and at increased cardiovascular risk in an analysis of SURPASS-4.
DiabetesWise Pro lets clinicians compare diabetes devices for a specific patient and provides the steps for ordering the device based on insurance type.
The Abbott FreeStyle Libre 3 is the smallest, thinnest, and most accurate 14-day CGM with a 7.9% MARD, the company says.
A new survey of youth aged 14 to 24 years provides significant support for integrating questions about social needs into routine clinical care.
